Abstract
Introduction: Alzheimer’s disease (AD) is the most common form of dementia. This disease is typified by neurodegeneration, neuroinflammation and oxidative stress hallmarked by the presence of neuropathological markers, such as amyloid-beta (Aβ) plaque deposition and the hyperphosphorylation of the tau protein that causes the formation of neurofibrillary tangles (NFTs). This results in cognitive and behavioural impairments often observed in those living with AD. Despite a progressive increase in disease burden, no current AD treatment options exist that cure the disease, nor do any current options stop or reverse disease-relevant pathologies, instead only attenuating symptoms. Preclinical mouse models of AD, such as the APP/PS1 mouse model, mirror AD-specific neuropathological, cognitive, and behavioural outcomes observed in human cases of AD, allowing this model to allow insight into the preclinical applicability of therapeutic disease interventions. Current preclinical evidence suggests that cannabis extracts may be able to lessen AD-related Aβ plaque deposition and NFT formation, consequently improving cognitive and behavioural outcomes such as object recognition and working memory through the presence of CBD, THC, and multiple other cannabinoids, terpenes and flavonoids contributing to the synergistic benefits of the ‘entourage effect’. Thus, this thesis sought to evaluate the effectiveness of 125 mg/kg CBD- rich cannabis extract (Eve) in treating AD-related behaviours in the APP/PS1 transgenic mouse model.Summary and Conclusion: The APP/PS1 mouse model exhibited hypolocomotion, reduced social interaction, and a moderate spatial learning impairment. Importantly, 125 mg/kg CBD- rich cannabis extract (Eve) increased explorative behaviours in the elevated plus maze, suggesting a beneficial effect of Eve on anxiety-related behaviours. However, Eve did not reverse social interaction deficits present in APP/PS1 mice. Future research concerning cannabis extracts should consider altering the ratio of CBD:THC to assess the effectiveness of alternate doses. Additionally, future studies should test APP/PS1 mice at 8-12 months to analyse the effects of Eve in advanced-stage AD. In conclusion, this study suggests that 125 mg/kg Eve imparts therapeutic benefits on certain AD-relevant behavioural aspects observed in people living with AD.
| Date of Thesis submission | 2023 |
|---|---|
| Original language | English |
| Awarding Institution |
|
| Supervisor | Tim Karl (Supervisor) |
Cite this
- Standard